GEPOPRETEKTOR TASIRLI PREPARATOARNING ISHLAB CHIQARISH TEXNOLOGIYASI
Article Sidebar
Main Article Content
Аннотация:
Ushbu maqola gepatoprotektiv tabletka preparatlarining ishlab chiqarish texnologiyasi va sifat ko‘rsatkichlarini nazariy tahlil asosida o‘rganishga bag‘ishlangan. Maqolada silaymarin asosidagi tabletka gepatoprotektiv dori shakllarining biofarmatsevtik asoslari, ishlab chiqarish texnologiyasining texnologik xususiyatlari, yordamchi moddalar kombinatsiyasining ratsionalligi va sifat nazorati ko‘rsatkichlarining O‘zDF, USP 46 hamda ICH Q6A xalqaro standartlariga muvofiqligi ko‘rib chiqilgan.
Article Details
Как цитировать:
Библиографические ссылки:
Abenavoli, L., Capasso, R., Milic, N., & Capasso, F. (2010). Milk thistle in liver diseases: Past, present, future. Phytotherapy Research, 24(10), 1423–1432. https://doi.org/10.1002/ptr.3207
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413–420. https://doi.org/10.1023/A:1016212804288
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. Journal of Hepatology, 70(1), 151–171. https://doi.org/10.1016/j.jhep.2018.09.014
Aulton, M. E., & Taylor, K. M. G. (2018). Aulton's pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.
Ergashev, B. X., & Toshmatov, N. A. (2021). O'zbekistonda jigar kasalliklarining epidemiologik ko'rsatkichlari va davolash muammolari. O'zbek tibbiyot jurnali, 3(2), 45–51.
Flora, K., Hahn, M., Rosen, H., & Benner, K. (1998). Milk thistle (Silybum marianum) for the therapy of liver disease. American Journal of Gastroenterology, 93(2), 139–143. https://doi.org/10.1111/j.1572-0241.1998.00139.x
ICH Expert Working Group. (2009). Pharmaceutical development Q8(R2). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
ICH Expert Working Group. (1999). Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances Q6A. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
Loguercio, C., & Festi, D. (2011). Silybin and the liver: From basic research to clinical practice. World Journal of Gastroenterology, 17(18), 2288–2301. https://doi.org/10.3748/wjg.v17.i18.2288
Morazzoni, P., & Bombardelli, E. (1995). Silybum marianum (Carduus marianus). Fitoterapia, 66(1), 3–42.
Nazarov, F. A., Xoliqov, A. B., & Raximov, D. S. (2022). O'zbekiston farmatsevtika bozorida gepatoprotektiv dori vositalarining tahlili. Farmatsiya va farmakologiya, 10(1), 18–25.
Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (Eds.). (2020). Handbook of pharmaceutical excipients (9th ed.). Pharmaceutical Press.
Sonnenbichler, J., Scalera, F., Sonnenbichler, I., & Weyhenmeyer, R. (1999). Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. Journal of Pharmacology and Experimental Therapeutics, 290(3), 1375–1383.
Stickel, F., & Schuppan, D. (2007). Herbal medicine in the treatment of liver diseases. Digestive and Liver Disease, 39(4), 293–304. https://doi.org/10.1016/j.dld.2006.11.004
United States Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary (USP 46–NF 41). United States Pharmacopeial Convention.
Verma, S., & Bhargava, A. (2013). Formulation and evaluation of fast dissolving tablets of silymarin using superdisintegrants. International Journal of Pharmaceutical Sciences and Research, 4(8), 3022–3028.
Wagner, H. (1981). Antihepatotoxic flavonoids. In J. B. Harborne & T. J. Mabry (Eds.), The flavonoids: Advances in research (pp. 545–590). Chapman & Hall.
Wichtl, M. (Ed.). (2004). Herbal drugs and phytopharmaceuticals: A handbook for practice on a scientific basis (3rd ed.). Medpharm Scientific Publishers.
World Health Organization. (2020). WHO model list of essential medicines (22nd ed.). World Health Organization.